* Avidity Biosciences Inc RNA.OQ reported a quarterly
adjusted
loss of 65 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -66 cents. The mean expectation of
eight analysts for the quarter was for a loss of 79 cents per
share. Wall Street expected results to range from -94 cents
to -60 cents per share.
* Revenue fell 11.7% to $2.05 million from a year ago;
analysts
expected $2.64 million.
* Avidity Biosciences Inc's reported EPS for the quarter was
a
loss of 65 cents.
* The company reported a quarterly loss of $70.79 million.
* Avidity Biosciences Inc shares had risen by 2.5% this
quarter and gained 362.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 2.1%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Avidity
Biosciences Inc is $56.00
This summary was machine generated from LSEG data August 9 at
08:51 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.79 -0.65 Beat
Mar. 31 2024 -0.78 -0.79 Missed
Dec. 31 2023 -0.66 -0.79 Missed
Sep. 30 2023 -0.77 -0.71 Beat